This Article Full Text (PDF) Correction (v54,p3074) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kamesaki, S. Articles by Cossman, J. Search for Related Content PubMed PubMed Citation Articles by Kamesaki, S. Articles by Cossman, J.

bcl-2 Protein Inhibits Etoposide-induced Apoptosis through Its Effects on Events Subsequent to Topoisomerase II-induced DNA Strand Breaks and Their Repair¹

Department of Pathology [S. K., H. K., J. C.] and Radiation Medicine [T. J. J.], Georgetown University School of Medicine, Washington, D.C. 20007, and Laboratory of Molecular Pharmacology [A. T., Y. P.], Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892

Previous studies have shown that bcl-2 overexpression can inhibit apoptosis induced by DNA-damaging agents widely used in cancer chemotherapy, including X-irradiation, alkylating agents (hydroperoxycyclophosphamide, etc.), and topoisomerase II inhibitors (etoposide, etc.). However, little is known about the mechanism by which bcl-2 overexpression inhibits apoptosis triggered by these agents. In this study, we examined whether bcl-2 overexpression could have effects on etoposide-induced DNA damage and its repair. For these experiments, we developed CH31 clones (mouse B-cells) stably transfected with human bcl-2 sense plasmids and compared these clones with a parental CH31 clone or CH31 clones with antisense plasmids. Overexpression of bcl-2 protein inhibited etoposide-induced apoptosis and cytotoxicity. However, there was no or little difference in the production and repair of DNa-protein cross-links, DNA single-strand breaks, and double-strand breaks among a parental CH31 clone and CH31 clones with human bcl-2 sense or antisense plasmids. These findings indicate that (a) apoptosis or cytotoxicity induced by etoposide can be separated into early events (formation of double-strand breaks, DNA single-strand breaks, and double-strand breaks) and later events (secondary DNA fragmentation or cell death) and (b) bcl-2 inhibits apoptosis and cytotoxicity induced by etoposide at some steps between these events.

¹ This work was supported by grants to J. C. (ACS-PDT428) and T. J. J. (CA-48716).

² To whom requests for reprints should be addressed, at Department of Pathology, Georgetown University School of Medicine, 3900 Reservoir Road, N.W., Washington, DC 20007.

Received 3/ 8/93. Accepted 7/12/93.

This article has been cited by other articles:

				L. Benimetskaya, K. Ayyanar, N. Kornblum, D. Castanotto, J. Rossi, S. Wu, J. Lai, B. D. Brown, N. Popova, P. Miller, et al. Bcl-2 Protein in 518A2 Melanoma Cells In vivo and In vitro. Clin. Cancer Res., August 15, 2006; 12(16): 4940 - 4948. [Abstract] [Full Text] [PDF]

				J. C. Lai, L. Benimetskaya, A. Khvorova, S. Wu, E. Hua, P. Miller, and C.A. Stein Phosphorothioate oligodeoxynucleotides and G3139 induce apoptosis in 518A2 melanoma cells Mol. Cancer Ther., February 1, 2005; 4(2): 305 - 315. [Abstract] [Full Text] [PDF]

				L. Benimetskaya, J. C. Lai, A. Khvorova, S. Wu, E. Hua, P. Miller, L.-M. Zhang, and C. A. Stein Relative Bcl-2 Independence of Drug-Induced Cytotoxicity and Resistance in 518A2 Melanoma Cells Clin. Cancer Res., December 15, 2004; 10(24): 8371 - 8379. [Abstract] [Full Text] [PDF]

				A. Raffo, J. C. Lai, C. A. Stein, P. Miller, S. Scaringe, A. Khvorova, and L. Benimetskaya Antisense RNA Down-Regulation of bcl-2 Expression in DU145 Prostate Cancer Cells Does Not Diminish the Cytostatic Effects of G3139 (Oblimersen) Clin. Cancer Res., May 1, 2004; 10(9): 3195 - 3206. [Abstract] [Full Text] [PDF]

				J. C. Lai, L. Benimetskaya, R. M. Santella, Q. Wang, P. S. Miller, and C. A. Stein G3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense manner Mol. Cancer Ther., October 1, 2003; 2(10): 1031 - 1043. [Abstract] [Full Text]

				A C Okaro, D A Fennell, M Corbo, B R Davidson, and F E Cotter Pk11195, a mitochondrial benzodiazepine receptor antagonist, reduces apoptosis threshold in Bcl-XL and Mcl-1 expressing human cholangiocarcinoma cells Gut, October 1, 2002; 51(4): 556 - 561. [Abstract] [Full Text] [PDF]

				A. H. Boulares, A. J. Zoltoski, Z. A. Sherif, A. G. Yakovlev, and M. E. Smulson The Poly(ADP-ribose) Polymerase-1-regulated Endonuclease DNAS1L3 Is Required for Etoposide-induced Internucleosomal DNA Fragmentation and Increases Etoposide Cytotoxicity in Transfected Osteosarcoma Cells Cancer Res., August 1, 2002; 62(15): 4439 - 4444. [Abstract] [Full Text] [PDF]

				Y. Liang, K. D. Nylander, C. Yan, and N. F. Schor Role of Caspase 3-Dependent Bcl-2 Cleavage in Potentiation of Apoptosis by Bcl-2 Mol. Pharmacol., January 1, 2002; 61(1): 142 - 149. [Abstract] [Full Text] [PDF]

				E. U. Kurz, S. E. Wilson, K. B. Leader, B. P. Sampey, W. P. Allan, J. C. Yalowich, and D. J. Kroll The Histone Deacetylase Inhibitor Sodium Butyrate Induces DNA Topoisomerase II{alpha} Expression and Confers Hypersensitivity to Etoposide in Human Leukemic Cell Lines Mol. Cancer Ther., December 1, 2001; 1(2): 121 - 131. [Abstract] [Full Text] [PDF]

				P. S. Schwartz and D. J. Waxman Cyclophosphamide Induces Caspase 9-Dependent Apoptosis in 9L Tumor Cells Mol. Pharmacol., December 1, 2001; 60(6): 1268 - 1279. [Abstract] [Full Text] [PDF]

				S. Talapatra and C. B. Thompson Growth Factor Signaling in Cell Survival: Implications for Cancer Treatment J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 873 - 878. [Abstract] [Full Text]

				S. Meintieres, A. Biola, M. Pallardy, and D. Marzin Apoptosis can be a confusing factor in in vitro clastogenic assays Mutagenesis, May 1, 2001; 16(3): 243 - 250. [Abstract] [Full Text] [PDF]

				T. S. Lawrence, M. A. Davis, A. Hough, and A. Rehemtulla The Role of Apoptosis in 2',2'-Difluoro-2'-deoxycytidine (Gemcitabine)-mediated Radiosensitization Clin. Cancer Res., February 1, 2001; 7(2): 314 - 319. [Abstract] [Full Text]

				R. J. Klasa, A. F. List, and B. D. Cheson Rational Approaches to Design of Therapeutics Targeting Molecular Markers Hematology, January 1, 2001; 2001(1): 443 - 462. [Abstract] [Full Text] [PDF]

				D. E. Lopes de Menezes, N. Hudon, N. McIntosh, and L. D. Mayer Molecular and Pharmacokinetic Properties Associated with the Therapeutics of Bcl-2 Antisense Oligonucleotide G3139 Combined with Free and Liposomal Doxorubicin Clin. Cancer Res., July 1, 2000; 6(7): 2891 - 2902. [Abstract] [Full Text]

				M. Konopleva, A. M. Tari, Z. Estrov, D. Harris, Z. Xie, S. Zhao, G. Lopez-Berestein, and M. Andreeff Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins Blood, June 15, 2000; 95(12): 3929 - 3938. [Abstract] [Full Text] [PDF]

				R. J. Klasa, M. B. Bally, R. Ng, J. H. Goldie, R. D. Gascoyne, and F. M. P. Wong Eradication of Human Non-Hodgkin's Lymphoma in SCID Mice by BCL-2 Antisense Oligonucleotides Combined with Low-Dose Cyclophosphamide Clin. Cancer Res., June 1, 2000; 6(6): 2492 - 2500. [Abstract] [Full Text]

				C. GARRIDO, J.-M. BRUEY, A. FROMENTIN, A. HAMMANN, A. P. ARRIGO, and E. SOLARY HSP27 inhibits cytochrome c-dependent activation of procaspase-9 FASEB J, November 1, 1999; 13(14): 2061 - 2070. [Abstract] [Full Text]

				A.-M. C. Dingemans, M. A. Witlox, R. A. L. M. Stallaert, P. van der Valk, P. E. Postmus, and G. Giaccone Expression of DNA Topoisomerase II{{alpha}} and Topoisomerase II{beta} Genes Predicts Survival and Response to Chemotherapy in Patients with Small Cell Lung Cancer Clin. Cancer Res., August 1, 1999; 5(8): 2048 - 2058. [Abstract] [Full Text] [PDF]

				L. A. Hogarth and A. G. Hall Increased BAX Expression Is Associated With an Increased Risk of Relapse in Childhood Acute Lymphocytic Leukemia Blood, April 15, 1999; 93(8): 2671 - 2678. [Abstract] [Full Text] [PDF]

				J. L. Kenney, M. E. Guinness, T. Curiel, and J. Lacy Antisense to the Epstein-Barr Virus (EBV)-Encoded Latent Membrane Protein 1 (LMP-1) Suppresses LMP-1 and Bcl-2 Expression and Promotes Apoptosis in EBV-Immortalized B Cells Blood, September 1, 1998; 92(5): 1721 - 1727. [Abstract] [Full Text] [PDF]

				E. Willmore, A. J. Frank, K. Padget, M. J. Tilby, and C. A. Austin Etoposide Targets Topoisomerase IIalpha and IIbeta in Leukemic Cells: Isoform-Specific Cleavable Complexes Visualized and Quantified In Situ by a Novel Immunofluorescence Technique Mol. Pharmacol., July 1, 1998; 54(1): 78 - 85. [Abstract] [Full Text]

				C. M. Eischen, T. J. Kottke, L. M. Martins, G. S. Basi, J. S. Tung, W. C. Earnshaw, P. J. Leibson, and S. H. Kaufmann Comparison of Apoptosis in Wild-Type and Fas-Resistant Cells: Chemotherapy-Induced Apoptosis Is Not Dependent on Fas/Fas Ligand Interactions Blood, August 1, 1997; 90(3): 935 - 943. [Abstract] [Full Text] [PDF]

				J. Park, I. Kim, Y. J. Oh, K.-w. Lee, P.-L. Han, and E.-J. Choi Activation of c-Jun N-terminal Kinase Antagonizes an Anti-apoptotic Action of Bcl-2 J. Biol. Chem., July 4, 1997; 272(27): 16725 - 16728. [Abstract] [Full Text] [PDF]

				Y. A. Hannun Apoptosis and the Dilemma of Cancer Chemotherapy Blood, March 15, 1997; 89(6): 1845 - 1853. [Full Text] [PDF]

				P. Zhou, L. Qian, K. M. Kozopas, and R. W. Craig Mcl-1, a Bcl-2 Family Member, Delays the Death of Hematopoietic Cells Under a Variety of Apoptosis-Inducing Conditions Blood, January 15, 1997; 89(2): 630 - 643. [Abstract] [Full Text] [PDF]

				K. R. Hande The Importance of Drug Scheduling in Cancer Chemotherapy: Etoposide as an Example Oncologist, August 1, 1996; 1(4): 234 - 239. [Abstract] [Full Text] [PDF]

				K. Hande The importance of drug scheduling in cancer chemotherapy: etoposide as an example Stem Cells, January 1, 1996; 14(1): 18 - 24. [Abstract]